These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20861237)

  • 1. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.
    Antoon JW; White MD; Meacham WD; Slaughter EM; Muir SE; Elliott S; Rhodes LV; Ashe HB; Wiese TE; Smith CD; Burow ME; Beckman BS
    Endocrinology; 2010 Nov; 151(11):5124-35. PubMed ID: 20861237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
    Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
    Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel sphingosine kinase inhibitor induces autophagy in tumor cells.
    Beljanski V; Knaak C; Smith CD
    J Pharmacol Exp Ther; 2010 May; 333(2):454-64. PubMed ID: 20179157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
    Beljanski V; Lewis CS; Smith CD
    Cancer Biol Ther; 2011 Mar; 11(5):524-34. PubMed ID: 21258214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
    Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase.
    Chumanevich AA; Poudyal D; Cui X; Davis T; Wood PA; Smith CD; Hofseth LJ
    Carcinogenesis; 2010 Oct; 31(10):1787-93. PubMed ID: 20688834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo.
    Venant H; Rahmaniyan M; Jones EE; Lu P; Lilly MB; Garrett-Mayer E; Drake RR; Kraveka JM; Smith CD; Voelkel-Johnson C
    Mol Cancer Ther; 2015 Dec; 14(12):2744-52. PubMed ID: 26494858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
    Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
    Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2.
    French KJ; Zhuang Y; Maines LW; Gao P; Wang W; Beljanski V; Upson JJ; Green CL; Keller SN; Smith CD
    J Pharmacol Exp Ther; 2010 Apr; 333(1):129-39. PubMed ID: 20061445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer.
    Antoon JW; Meacham WD; Bratton MR; Slaughter EM; Rhodes LV; Ashe HB; Wiese TE; Burow ME; Beckman BS
    J Mol Endocrinol; 2011 Jun; 46(3):205-16. PubMed ID: 21321095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
    Lewis CS; Voelkel-Johnson C; Smith CD
    Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer.
    Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S
    J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
    Zhou J; Chen J; Yu H
    Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
    Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
    J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.
    Antoon JW; White MD; Driver JL; Burow ME; Beckman BS
    Exp Biol Med (Maywood); 2012 Jul; 237(7):832-44. PubMed ID: 22859737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine kinase 2 inhibitor ABC294640 suppresses neuronal excitability and inhibits multiple endogenously and exogenously expressed voltage-gated ion channels in cultured cells.
    Zhang F; Hu W; Qu L; Cang C
    Channels (Austin); 2020 Dec; 14(1):216-230. PubMed ID: 32615066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
    Guan S; Liu YY; Yan T; Zhou J
    Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640.
    White MD; Chan L; Antoon JW; Beckman BS
    Anticancer Res; 2013 Sep; 33(9):3573-9. PubMed ID: 24023282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.